Rentschler selected to develop Alzheimer's inhibitor mAb for Probiodrug

By Dan Stanton contact

- Last updated on GMT

Rentschler selected to make Alzheimer's inhibitor mAb for Probiodrug

Related tags: Monoclonal antibodies

Probiodrug has selected German CMO Rentschler to develop its Alzheimer’s monoclonal antibody candidate.

Under terms of the deal, contract manufacturing organisation (CMO) Rentschler is charged with developing PBD-C06 - Probiodrug’s pGlu-Abeta-specific monoclonal antibody – from cell line development to preclinical and clinical biomanufacturing.

“Rentschler is a well-known and renowned CMO with a proven track record of over 40 years. They already have the required processes in place​,” Probiodrug’s CEO Konrad Glund told this publication.

He added Rentschler had been selected from a number of CMOs and “met the specifications and criteria required for this project.  Their experience and track record were notable and they are committed to meeting our aggressive timelines.”

The candidate itself is a chimeric, de-immunized monoclonal antibody being investigated by the Halle, Germany-headquartered biopharma firm as a potential treatment for Alzheimer’s disease.

The product targets and selectively clears the brain of existing pGlu-Abeta - the protein linked to the development of Alzheimer’s disease - leaving nontoxic forms of Abeta untouched, Glund said.

“PBD-C06 [has a] high specificity for pGlu-Abeta. Data from preventative and therapeutic studies in animal models have shown that PBD-C06 reduces soluble and insoluble pGlu-Abeta as well as total Abeta, and also rescues behavioural deficits.”

Senior Vice President of Project Management at Rentschler, Klaus Schoepe, said the CMO was “excited” to develop the mAb.

“We are confident our long-term expertise will deliver a first-class quality product and meet the challenging timelines of this project, which is targeting a disease affecting a substantial number of elderly people.”

Related topics: Contract Manufacturing

Related news

Related products

show more

baxter_bloomington_facility_larger

Sterile Injectables Contract Manufacturing

Baxter BioPharma Solutions | 02-Apr-2018 | Product Brochure

Baxter BioPharma Solutions' award-winning facility in Bloomington, Indiana, USA, is a leader in sterile contract manufacturing of injectable products.

lyo_development

Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

How will Brexit affect the Pharmaceutical Industry?

How will Brexit affect the Pharmaceutical Industry?

Source BioScience Ltd | 08-Mar-2018 | Technical / White Paper

Have you prepared your strategy for the outcome of Brexit to ensure that you can continue to supply the UK market?
Source BioScience is a CRO with...

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

Related suppliers

Follow us

Products

View more